Chemoinformaics analysis of RHAMNOVERACINTINE
| Molecular Weight | 529.762 | nRot | 4 |
| Heavy Atom Molecular Weight | 478.354 | nRig | 31 |
| Exact Molecular Weight | 529.377 | nRing | 6 |
| Solubility: LogS | -4.01 | nHRing | 2 |
| Solubility: LogP | 5.053 | No. of Aliphatic Rings | 6 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 4 |
| Atoms Count | 89 | No. of Aliphatic Hetero Cycles | 2 |
| No. of Heavy Atom | 38 | No. of Aromatic Carbocycles | 0 |
| nHetero | 6 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 3 |
| No. of Hydrogen atom | 51 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 32 | No. of Saturated Rings | 4 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 5 | No. of Arom Bond | 0 |
| nHA | 6 | APOL | 92.5564 |
| nHD | 3 | BPOL | 55.7756 |
| QED | 0.444 |
| Synth | 5.224 |
| Natural Product Likeliness | 2.444 |
| NR-PPAR-gamma | 0.012 |
| Lipinski | Rejected |
| Pfizer | Accepted |
| GSK | Rejected |
| Golden Triangle | Rejected |
| Pgp-inh | 0.849 |
| Pgp-sub | 0.006 |
| HIA | 0.161 |
| CACO-2 | -4.769 |
| MDCK | 0.000022 |
| BBB | 0.196 |
| PPB | 0.96734 |
| VDSS | 1.868 |
| FU | 0.0189955 |
| CYP1A2-inh | 0.003 |
| CYP1A2-sub | 0.412 |
| CYP2c19-inh | 0.015 |
| CYP2c19-sub | 0.943 |
| CYP2c9-inh | 0.029 |
| CYP2c9-sub | 0.163 |
| CYP2d6-inh | 0.001 |
| CYP2d6-sub | 0.863 |
| CYP3a4-inh | 0.109 |
| CYP3a4-sub | 0.478 |
| CL | 6.982 |
| T12 | 0.024 |
| hERG | 0.051 |
| Ames | 0.07 |
| ROA | 0.18 |
| SkinSen | 0.011 |
| Carcinogencity | 0.097 |
| EI | 0.005 |
| Respiratory | 0.898 |
| NR-Aromatase | 0.053 |
| Antiviral | Yes |
| Prediction | 0.590274 |